Add to ORKGRRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization
BackgroundSmall cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid ...
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in Englis...
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in Englis...
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced ...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, in...
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, in...
BACKGROUND: This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 ...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mu...
BackgroundRRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In t...
Background: RRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In...
Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after fa...
BackgroundSmall cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid ...
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in Englis...
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in Englis...
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced ...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, in...
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, in...
BACKGROUND: This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 ...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mu...
BackgroundRRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In t...
Background: RRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In...
Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after fa...
BackgroundSmall cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid ...
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in Englis...
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in Englis...